← Back to search

ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.

Proceedings of the National Academy of Sciences of the United States of America · 2013 · Vol. 110 (8) · pp. E736-45

Abstract

Transactivating response region DNA binding protein (TDP-43) is the major protein component of ubiquitinated inclusions found in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) with ubiquitinated inclusions. Two ALS-causing mutants (TDP-43(Q331K) and TDP-43(M337V)), but not wild-type human TDP-43, are shown here to provoke age-dependent, mutant-dependent, progressive motor axon degeneration and motor neuron death when expressed in mice at levels and in a cell type-selective pattern similar to endogenous TDP-43. Mutant TDP-43-dependent degeneration of lower motor neurons occurs without: (i) loss of TDP-43 from the corresponding nuclei, (ii) accumulation of TDP-43 aggregates, and (iii) accumulation of insoluble TDP-43. Computational analysis using splicing-sensitive microarrays demonstrates alterations of endogenous TDP-43-dependent alternative splicing events conferred by both human wild-type and mutant TDP-43(Q331K), but with high levels of mutant TDP-43 preferentially enhancing exon exclusion of some target pre-mRNAs affecting genes involved in neurological transmission and function. Comparison with splicing alterations following TDP-43 depletion demonstrates that TDP-43(Q331K) enhances normal TDP-43 splicing function for some RNA targets but loss-of-function for others. Thus, adult-onset motor neuron disease does not require aggregation or loss of nuclear TDP-43, with ALS-linked mutants producing loss and gain of splicing function of selected RNA targets at an early disease stage.

Publication Types

["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, Non-P.H.S."]

Keywords

[]

MeSH Terms

["Amyotrophic Lateral Sclerosis", "Animals", "Cell Nucleus", "DNA-Binding Proteins", "Mice", "Mice, Transgenic", "Mutation", "RNA Splicing", "Real-Time Polymerase Chain Reaction", "Ubiquitination"]

Funding

R01 HG004659 NHGRI NIH HHS (United States)
T32 GM008666 NIGMS NIH HHS (United States)
R01 NS075449 NINDS NIH HHS (United States)
MC_G1000733 Medical Research Council (United Kingdom)
HG004659 NHGRI NIH HHS (United States)
NS075449 NINDS NIH HHS (United States)
T32 AG 000216 NIA NIH HHS (United States)
089701 Wellcome Trust (United Kingdom)
T32 AG000216 NIA NIH HHS (United States)
K99 NS075216 NINDS NIH HHS (United States)
G0300329 Medical Research Council (United Kingdom)
NS075216 NINDS NIH HHS (United States)
G0900688 Medical Research Council (United Kingdom)
RC1 NS069144 NINDS NIH HHS (United States)
NS069144 NINDS NIH HHS (United States)